---
title: "Fate Therapeutics gewährt neuem Mitarbeiter Aktienoptionen und RSUs als Einstiegsvergütung"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274709469.md"
datetime: "2026-02-03T21:05:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274709469.md)
  - [en](https://longbridge.com/en/news/274709469.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274709469.md)
---

# Fate Therapeutics gewährt neuem Mitarbeiter Aktienoptionen und RSUs als Einstiegsvergütung

Fate Therapeutics Inc. hat am 3. Februar 2026 bekannt gegeben, dass einem neu eingestellten nicht-exekutiven Mitarbeiter Aktienoptionen zum Erwerb von 120.000 Stammaktien zu einem Ausübungspreis von 1,19 US-Dollar sowie 90.000 Restricted Stock Units (RSUs) gewährt wurden. Die Zuteilungen erfolgten gemäß dem Amended and Restated Inducement Equity Plan und unterliegen einer vierjährigen Vesting-Periode. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9647528-en) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference](https://longbridge.com/en/news/282940584.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | AVTBF Stock News](https://longbridge.com/en/news/282741678.md)
- [Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham](https://longbridge.com/en/news/282904330.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)